152P Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): Interim analysis of a global real-world (RW) study
Year: 2024
Type: article
Study design: Observational Study
Abstract: There is an unmet need for patients (pts) with unresectable stage III EGFRm NSCLC who receive CRT. Consolidative immunotherapy has limited efficacy and no EGFR-TKIs are approved in this setting. We report interim data from a global, retrospective RW study of pts with unresectable stage III EGFRm NSCLC who received CRT.
Source: ESMO Open
Authors: J. Neal, J.B. Lee, M-J. Ahn, R. Ariyasu, C. Nash, D. Smith, S. Nagar, M. Jimenez, D.A. Kahangire, Y.J. Kim, F. Nasirova, S.H. Lin
Institutions: Stanford Medicine, Stanford University, Yonsei University, Severance Hospital, Samsung Medical Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Northeast Georgia Medical Center, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, RTI Health Solutions, AstraZeneca (United Kingdom), AstraZeneca (Canada), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,730
Funder: AstraZeneca
OpenAlex ID: W4393166273